The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain

Document Type : Abstracts

Abstract

The first Remodulin® I-jet pump implantation in 
Egypt was performed in 2017 at the Magdy 
Yacoub Aswan Heart Centre. Face flushing, 
headaches, jaw pain, cramping, diarrhea, and pain 
at the insertion site are major side effects of the 
drug. According to clinical studies, site pain 
reaches up to 93% of patients with Remodulin® 
pump. Some patients at Aswan Heart Center want 
to discontinue the treatment because of the intense 
pain

Files

Share

How to cite

Statistics